Related references
Note: Only part of the references are listed.Depression in multiple sclerosis: A long-term longitudinal study
Marcus W. Koch et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Observational study of spinal muscular atrophy type I and implications for clinical trials
Richard S. Finkel et al.
NEUROLOGY (2014)
Importance of Preclinical Research in the Development of Neuroprotective Strategies for Ischemic Stroke
Ain A. Neuhaus et al.
JAMA NEUROLOGY (2014)
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial
Merit E. Cudkowicz et al.
LANCET NEUROLOGY (2013)
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial
LANCET NEUROLOGY (2013)
Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data
Sarah J. Tabrizi et al.
LANCET NEUROLOGY (2013)
A Randomized, Double-Blind, Placebo-Controlled Trial of Pridopidine in Huntington's Disease
Karl Kieburtz et al.
MOVEMENT DISORDERS (2013)
Treatment trials in progressive MS-current challenges and future directions
Marcus W. Koch et al.
NATURE REVIEWS NEUROLOGY (2013)
Novel Approaches to Neuroprotection Trials in Acute Ischemic Stroke
Michael Tymianski
STROKE (2013)
What is the clinically relevant change on the ADAS-Cog?
Anette Schrag et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data
Sarah J. Tabrizi et al.
LANCET NEUROLOGY (2012)
Childhood spinal muscular atrophy: controversies and challenges
Eugenio Mercuri et al.
LANCET NEUROLOGY (2012)
Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures
D. Ontaneda et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Spinal Muscular Atrophy: A Clinical and Research Update
Jennifer A. Markowitz et al.
PEDIATRIC NEUROLOGY (2012)
Current therapeutic procedures in Dravet syndrome
Catherine Chiron
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2011)
Amyotrophic lateral sclerosis
Matthew C. Kiernan et al.
LANCET (2011)
A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS
M. S. Freedman et al.
NEUROLOGY (2011)
CURRENT CONCEPTS Drug-Resistant Epilepsy
Patrick Kwan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology
Alexis Arzimanoglou et al.
LANCET NEUROLOGY (2009)
The search for responsive clinical endpoints in primary progressive multiple sclerosis
L. V. A. E. Bosma et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
Fatigue, depression and progression in multiple sclerosis
M. Koch et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Is it time to definitely abandon neuroprotection in acute ischemic stroke?
Maria Luisa Sacchetti
STROKE (2008)
NXY-059 for the treatment of acute stroke - Pooled analysis of the SAINT I and II trials
Hans-Christoph Diener et al.
STROKE (2008)
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
Paul H. Gordon et al.
LANCET NEUROLOGY (2007)
Perspectives on clinical trials in spinal muscular atrophy
Kathryn J. Swoboda et al.
JOURNAL OF CHILD NEUROLOGY (2007)
The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial
Anthony G. Marson et al.
LANCET (2007)
The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial
Anthony G. Marson et al.
LANCET (2007)
Screening potential therapies - Lessons learned from new paradigms used in Parkinson disease
Barbara C. Tilley et al.
STROKE (2007)
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky et al.
ANNALS OF NEUROLOGY (2007)
Therapeutic strategies for the treatment of stroke
A. Richard Green et al.
DRUG DISCOVERY TODAY (2006)
Optimizing the ongoing search for new treatments for Parkinson disease - Using futility designs
BC Tilley et al.
NEUROLOGY (2006)
1,026 experimental treatments in acute stroke
VE O'Collins et al.
ANNALS OF NEUROLOGY (2006)
Challenges and opportunities in clinical trials for spinal muscular atrophy
D Hirtz et al.
NEUROLOGY (2005)
Applying a phase II futility study design to therapeutic stroke trials
YY Palesch et al.
STROKE (2005)
Frontotemporal dementia progresses to death faster than Alzheimer disease
ED Roberson et al.
NEUROLOGY (2005)
Rate of progression differs in frontotemporal dementia and Alzheimer disease
K Rascovsky et al.
NEUROLOGY (2005)
Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial
A Marson et al.
LANCET (2005)
A responsive outcome for Parkinson's disease neuroprotection futility studies
JJ Elm et al.
ANNALS OF NEUROLOGY (2005)
An efficient multi-stage, single-arm Phase II futility design for ALS
YY Palesch et al.
AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS (2004)
Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies
M Pocchiari et al.
BRAIN (2004)
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
JA Cohen et al.
NEUROLOGY (2002)
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
M Van Glabbeke et al.
EUROPEAN JOURNAL OF CANCER (2002)
Sample size tables for exact single-stage phase II designs
RP A'Hern
STATISTICS IN MEDICINE (2001)
Share Paper
